ESTRO 2025 - Abstract Book

S2321

Interdisciplinary – Health economics & health services research

ESTRO 2025

The majority of EMBRACe-GM patients (21/26, 81%) approached were eligible and consented, whilst only 48/124 (39%) were eligible and consented for ReCoRd (table 1). The most prominent reason for ineligibility within the ReCoRd study was technical issues (37/44, 84%) whereby patients did not own a smartphone able to connect with the smartwatch compared to EMBRACe-GM where no patients were ineligible for this metric.

Of the ReCoRd cohort, 87.5% found the watch tolerable to wear throughout the entirety of the trial period (figure 2), whilst there was a preference within the EMBRACe-GM cohort for the rings (85%) compared to the smartwatches (55%). Less ReCoRd participants (16%) removed the watch during the study period for comfort reasons compared to 40% in the EMBRACe-GM cohort.